Trastuzumab-qyyp 150 mg [Trazimera]
RxNorm 2472792

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2472792 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: trastuzumab-qyyp 150 mg [Trazimera].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Trastuzumab-qyyp 150 mg [Trazimera]
AUI:12530041
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Trastuzumab-qyyp 150 mg [Trazimera]
(Atom ID: 12530041)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
trastuzumab-qyyp 150 MG [Trazimera]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2472792
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12530041
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2472792
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN ACTIVATED
03/31/2021
Date the RxNorm atom was reactivated
RXN OBSOLETED
01/27/2021
Date the RxNorm atom became obsolete

Patient Education

Fam-trastuzumab deruxtecan-nxki Injection


Fam-trastuzumab deruxtecan-nxki injection is used to treat a certain type of breast cancer that cannot be removed by surgery or that has spread to other parts of the body after at least two other breast cancer treatments. It is also used to treat certain types of gastric cancer (cancer of the stomach) in adults that has spread to nearby tissues or to other parts of the body after receiving another treatment. Fam-trastuzumab deruxtecan-nxki is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.
[Learn More]


Trastuzumab Injection


Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.
[Learn More]


* Please review the disclaimer below.